

## Hybrigenics 2012 first-half results

- **+5% growth of Hybrigenics' operating revenues**
- **An exceptional revenue of EUR 0.96 million**
- **EUR 3.3 million raised to finance the clinical study of oral inecalcitol in chronic lymphocytic leukemia**

**Paris, 18 October 2012** – Hybrigenics (ALHYG), a bio-pharmaceutical company listed on Alternext (NYSE-Euronext) in Paris, with a focus on research and development of new treatments against proliferative diseases and specialised in protein interactions, today presents its consolidated accounts for the first half of 2012.

### 2012 first-half results

| EUR (million)                            | H1 2012     | H1 2011 | Change (%)   |
|------------------------------------------|-------------|---------|--------------|
| <b>Total operating revenues</b>          | <b>2.1</b>  | 2.0     | <b>+5%</b>   |
| <b>Exceptional revenue</b>               | <b>1.0</b>  | ---     | ---          |
| <b>Total revenues</b>                    | <b>3.1</b>  | 2.0     | <b>+55%</b>  |
| <b>Operating costs</b>                   | <b>4.6</b>  | 4.4     | <b>+5%</b>   |
| <b>Operating loss</b>                    | <b>-2.5</b> | -2.4    | <b>+4%</b>   |
| <b>Net loss</b>                          | <b>-1.5</b> | -2.1    | <b>-29%</b>  |
| <b>Net cash position (end of period)</b> | <b>4.1</b>  | 2.0     | <b>+105%</b> |

Hybrigenics' consolidated operating revenues and operating costs both grew by 5%. Operating loss increased from €2.4 to €2.5 million (+4%). An exceptional revenue of €0.96 million resulting from the conversion of a loan into a subsidy by the French Ministry of Industry (cf. Hybrigenics' press release of August 28<sup>th</sup>, 2012) is the non-recurring reason for the 55% increase in total revenues and for the 29% decrease in net loss.

Hybrigenics' cash position on June 30<sup>th</sup>, 2012 amounted to €4.1 million compared to €2.7 million on December 31<sup>st</sup>, 2011, and €2.0 million on June 30<sup>th</sup>, 2011. During H1 2012, a total of €3.8 million has been raised: €3.3 million from two consecutive PIPEs in March and €0.5 million earlier in the year from drawings on the equity line agreement with the American fund Yorkville Global Advisors; €8.2 million were still available on this line as of June 30<sup>th</sup>, 2012.

### **Launch of Phase II clinical study of inecalcitol in chronic lymphocytic leukemia (CLL)**

The €3.3 million raised in March 2012 were ear-marked to finance the clinical Phase II study of inecalcitol in CLL. As planned, the trial has started enrolling patients in September (cf Hybrigenics' press release of September 11<sup>th</sup>, 2012).

*"Hybrigenics has again delivered a solid business performance during the first half of 2012, with an exceptional revenue of 0.96 million euro booked on top of it," said Rémi Delansorne. "The clinical phase II study of inecalcitol in CLL was successfully financed by a project-driven capital raise in March and has been efficiently implemented within six months".*

#### **About Hybrigenics**

Hybrigenics ([www.hybrigenics.com](http://www.hybrigenics.com)) is a bio-pharmaceutical company listed (ALHYG) on Alternext (NYSE-Euronext) in Paris, focusing its internal R&D programs on innovative targets and therapies for the treatment of proliferative cancerous or non-cancerous diseases.

Hybrigenics' current development program is based on inecalcitol, a vitamin D receptor agonist active by oral administration. Oral inecalcitol has shown excellent tolerance and strong presumption of efficacy for the first-line treatment of metastatic castrate-resistant prostate cancer in combination with Taxotere<sup>®</sup>, which is the current gold-standard chemotherapeutic treatment for this indication. Oral inecalcitol has recently been studied in a clinical trial for the treatment of moderate-to-severe psoriasis, and is currently being tested in chronic lymphocytic leukemia patients.

Hybrigenics has a research collaboration with Servier on deubiquitinating enzymes and their inhibitors in oncology, neurology, psychiatry, rheumatology, ophthalmology, diabetes and cardiovascular diseases. Hybrigenics continues to build on its pioneer research position in the field of ubiquitin-specific proteases by exploring their role in other areas of particular relevance, such as inflammation and virology.

Hybrigenics Services ([www.hybrigenics-services.com](http://www.hybrigenics-services.com)), a fully-owned subsidiary, is the market leader in Yeast Two-Hybrid (Y2H) and related services to identify, validate and inhibit protein interactions for researchers in all areas of life sciences, using its ISO 9001-certified high-throughput Y2H screening platform, its sophisticated bioinformatics tools and extensive database, along with its chemical library and chemical screening platform.

\*\*\*

**HYBRIGENICS is listed on the Alternext by NYSE Euronext Paris**

**ISIN: FR0004153930 - Ticker: ALHYG**



#### **Hybrigenics**

Rémi Delansorne  
CEO  
Tel.: +33 (0)1 58 10 38 00  
[investors@hybrigenics.com](mailto:investors@hybrigenics.com)

#### **NewCap.**

Financial communication  
Axelle Vuillermet / Pierre Laurent  
Tel.: +33 (0)1 44 71 94 94  
[hybrigenics@newcap.fr](mailto:hybrigenics@newcap.fr)